Last edition
News about "Fluticasone Propionate Inhalation Aerosol "
Glenmark Specialty SA Receives US FDA Approval for Fluticasone Propionate Inhalation Aerosol USP
Glenmark Pharmaceuticals’s subsidiary Glenmark Specialty SA has received approval from the US Food and Drug Administration (FDA) for Fluticasone Propionate Inhalation Aerosol USP, 44 mcg per actuation, along with 180-day Competitive Generic Therapy exclusivity. The product has been deemed bioequivalent and therapeutically equivalent to Flovent HFA.
Fluticasone Propionate Inhalation Aerosol | 05/03/2026 | By Akanki | 126
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy